Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bluebird bio

Explore full profile

Integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing

Cambridge, United StatesFounded 1993Biotech & Life Sciences
Valuation $150M Market cap · 2026
Revenue $84M Latest reported FY

At a glance

Founded
1993
Headquarters
Cambridge, United States
Listing
IPO 2013
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later12 investors entered at this stage

Employees mapped 308 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 8 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
13 countries with
team presence
🇺🇸 United States93.5%
🇫🇷 France1.3%
🇿🇦 South Africa0.9%
🇮🇳 India0.9%
🇧🇷 Brazil0.5%
Top 5 of 13 shown
Web traffic by country
3.2K monthly visits
across markets
🇮🇳 India56.3%
🇺🇸 United States40.6%
Top 2 markets shown

Patents

Estimated portfolio value
$100M

43 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bluebird bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bluebird bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.